Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series
02 October 2019 - 8:30PM
Business Wire
Enrollment complete in the Phase 3 MOUNTAIN
Study evaluating SAGE-217 in the treatment of major depressive
disorder (MDD); topline results expected in 4Q 2019
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company
committed to developing novel therapies with the potential to
transform the lives of people with debilitating disorders of the
brain, today announced that the Company will participate in an
Executive Conference Call Series hosted by J.P. Morgan on Thursday,
October 3, 2019 at 10:00 AM EDT.
In conjunction with the webcast, the Company announced
enrollment for the Phase 3 MOUNTAIN Study evaluating the efficacy
and safety of SAGE-217 in patients with major depressive disorder
(MDD) is complete. The Company expects to report topline results in
the fourth quarter of 2019.
A live webcast of the call can be accessed on the investor page
of Sage's website at investor.sagerx.com. A replay of the webcast
will also be archived for up to 30 days on Sage's website following
the conference.
About Sage Therapeutics Sage Therapeutics is a
biopharmaceutical company committed to developing novel therapies
with the potential to transform the lives of people with
debilitating disorders of the brain. We are pursuing new pathways
with the goal of improving brain health, and our depression,
neurology and neuropsychiatry franchise programs aim to change how
brain disorders are thought about and treated. Our mission is to
make medicines that matter so people can get better, sooner. For
more information, please visit www.sagerx.com.
Forward-Looking Statements This release contains certain
statements regarding Sage's future expectations, plans and
prospects, including the anticipated timing for reporting of
top-line data from the MOUNTAIN study. These statements constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are neither promises nor guarantees of future
performance, and are subject to a variety of risks and
uncertainties, many of which are beyond our control, which could
cause actual results to differ materially from those contemplated
in these forward-looking statements, including the risk that we may
encounter issues or challenges in our collection, cleaning and
analysis of the data from the MOUNTAIN study which could cause
delay in reporting of results. Other risks related to our business
are discussed in the section entitled "Risk Factors" in our most
recent quarterly report filed with the Securities and Exchange
Commission (SEC), and discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the SEC. In addition, any forward-looking statements
represent our views only as of today, and should not be relied upon
as representing our views as of any subsequent date. We explicitly
disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005256/en/
Investor Contact Matt Calistri 617-914-2635
matthew.calistri@sagerx.com
Media Contact Alexis Smith 617-588-3740
alexis.smith@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2024 to May 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From May 2023 to May 2024